Courtney Flaherty

Articles

Ongoing ADC Development Continues to Gain Traction in Ovarian Cancer

January 24th 2024

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

Sacituzumab Govitecan Fails to Generate Survival Benefit in Advanced NSCLC

January 23rd 2024

The phase 3 EVOKE-01 trial did not meet its primary end point of significantly improved OS with sacituzumab govitecan vs docetaxel in pretreated NSCLC.

Grivas Expands on Key Data From the 2023 ESMO Congress in Urothelial Cancer

January 23rd 2024

Petros Grivas, MD, PhD, spotlights key advancements and research in urothelial cancer reported at the 2023 ESMO Congress, detailing findings from the phase 3 CheckMate 901, EV-302/KEYNOTE-A39, and THOR trials.

Patient Factors, Safety, and Long-Term Efficacy Best Inform Treatment Selection Across Hematologic Malignancies

January 22nd 2024

Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.

Taletrectinib Continues to Demonstrate High Clinical Activity in Advanced ROS1+ NSCLC

January 22nd 2024

Clinicians discuss data on the ROS1 TKI taletrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Emerging BTK-Directed Therapies Continue to Advance the Management of CLL

January 17th 2024

Michael Choi, MD, discusses several key considerations for the treatment of chronic lymphocytic leukemia.

FDA Grants Fast Track Status to NX-5948 for Relapsed/Refractory CLL/SLL

January 17th 2024

The FDA has granted fast-track status to NX-5948 for use in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Grivas Expands on Therapeutic Developments and Future Research Directions in GU Cancers

January 17th 2024

Petros Grivas, MD, PhD, discusses the role of PARP inhibitor regimens in prostate cancer, the importance of genetic testing in this setting, and more.

Randall Highlights the Evolving Role of Surgery in TGCT Management

January 16th 2024

R. Lor Randall, MD, FACS, discusses the early efficacy seen with vimseltinib monotherapy and pexidartinib plus surgery in tenosynovial giant cell tumors.

ctDNA Patterns May Predict Outcomes Achieved With mRNA-4157 Plus Pembrolizumab in High-Risk Melanoma

January 15th 2024

Jeffrey S. Weber, MD, PhD, expands on the potential utility of longitudinal ctDNA dynamics as a kinetic marker for clinical outcomes in melanoma.

Addition of Multifocal MRI-Directed SIB to SBRT Shows Acceptable Toxicity Profile in Prostate Cancer

January 12th 2024

Joshua Hurwitz, MD, shares how multifocal MRI-directed SIB plus SBRT was not linked with added toxicity vs unifocal SIB in patients with prostate cancer.

Shore Highlights Ongoing Efforts With PARP Inhibitors, Radioligand Therapy in Prostate Cancer

January 12th 2024

Neal Shore, MD, FACS, discusses attempts to expand the current prostate cancer armamentarium through the development of novel, targeted therapies.

Enzalutamide Intensifies the Activity of ADT Monotherapy and Expands Limited nmCSPC Treatment Armamentarium

January 11th 2024

Neal Shore, MD, FACS, highlights the significance of the FDA approval of enzalutamide in nonmetastatic castration-sensitive prostate cancer.

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors

January 9th 2024

Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.

FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer

January 8th 2024

The FDA has granted fast track designation to rinatabart sesutecan for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Practical Toxicity Management Awareness With FGFR Inhibitors Improves Real-World Patient Outcomes

January 8th 2024

Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.

Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification

January 7th 2024

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

Lifileucel Demonstrates Long-Term Efficacy and Survival Benefit in Advanced, Pretreated Melanoma

January 5th 2024

Lifileucel demonstrated clinically meaningful antitumor activity alongside early, durable responses in patients with advanced melanoma following progression on checkpoint inhibitors.

Lenvatinib Plus Pembrolizumab Fails to Improve OS and PFS Over Docetaxel in Stage IV NSCLC

January 4th 2024

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

Advani Spotlights Clinical Trial Implications Across Breast Cancer Subtypes

January 4th 2024

Pooja Advani, MBBS, MD, details key advancements and the significance of pivotal trials that were presented by her colleagues at a recent OncLive® State of the Science Summit™ on breast cancer, which she chaired.